Imatinib Novumgen

Imatinib, the active ingredient in Imatinib Novumgen, is a tyrosine kinase inhibitor presented as an oral dosage form for systemic use. It is employed in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors, targeting malignant cell proliferation in adult patients.

GNH USA supplies Imatinib Novumgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across markets.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, providing targeted therapy for specific cancers. - Chronic myeloid leukemia (CML): suppresses leukemic cell proliferation and induces remission. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and reduces disease progression. - Dermatofibrosarcoma protuberans (DFSP): promotes tumor regression and improves surgical outcomes. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control in combination regimens. - Other BCR‑ABL positive leukemias: provides therapeutic benefit as part of treatment protocols.

Imatinib may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild stomach upset. - Edema: swelling of extremities. - Fatigue: persistent tiredness. - Diarrhea: loose stools. Serious or Rare Side Effects: - Neutropenia: low white blood cell count. - Hepatotoxicity: liver injury. - Cardiac failure: reduced heart function.

When prescribing Imatinib, clinicians should observe several safety measures to minimize risks. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes periodically for signs of toxicity. - Evaluate cardiac status: perform ECG or echocardiogram in patients with existing heart disease. - Avoid use in patients with known hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution in pregnancy: limited data; weigh potential benefits against risks. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Imatinib interacts with several medicines that can alter its effectiveness or increase toxicity. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib plasma levels, risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce imatinib exposure, risk of treatment failure. - QT‑prolonging agents (e.g., sotalol, quinidine): may exacerbate cardiac rhythm disturbances. Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect, monitor INR. - CYP2C8 substrates (e.g., paclitaxel): possible altered metabolism, adjust dosing if needed. - Antacids containing aluminum or magnesium: may affect absorption, separate administration by at least 2 hours.